Reviva Pharmaceuticals Reports Positive 1-Year Phase 3 Results for Brilaroxazine in Schizophrenia, Highlighting Efficacy and Safety

Reviva Pharmaceuticals announced positive Phase 3 results for brilaroxazine in schizophrenia, demonstrating sustained efficacy across symptom domains, including negative symptoms, over one year. The open-label extension study also showed a well-tolerated safety profile with low adverse event rates and improvements in neuroinflammatory markers. These findings will support brilaroxazine's FDA registration, with Reviva hosting an investor webcast to discuss the data.

Analysis

Reviva Pharmaceuticals (NASDAQ: RVPH) has announced positive, full dataset results from its Phase 3 RECOVER open-label extension (OLE) study for brilaroxazine in treating schizophrenia, demonstrating robust and sustained broad-spectrum efficacy over one year. Key efficacy metrics showed significant improvements across all major symptom domains, including negative symptoms, with pooled brilaroxazine doses yielding a -18.1 point improvement in PANSS Total Score at 12 months (N=159) and a more pronounced -47.7 point improvement for rollover patients at 13 months (N=50). Personal and Social Performance scores improved by 11.3 points at 12 months. The drug also exhibited a well-tolerated safety profile, with only 8.5% of participants reporting treatment-emergent adverse events (TEAEs), predominantly mild (6.5%) or moderate (2.0%) and transient. Common TEAEs (≥2%) included headache (2.7%), insomnia (4.0%), sleep disturbance (2.9%), and mild tremor (3.1%). Notably, brilaroxazine was not associated with clinically meaningful changes in movement disorder scales, showed mild weight gain (1.52 kg over 1 year), and had no drug-related serious adverse events or major safety concerns like DILI or significant cardiac side effects. Furthermore, brilaroxazine improved multiple neuroinflammatory markers, which could enhance efficacy and mitigate side effects. The reported 35% discontinuation rate over one year was primarily attributed to withdrawal of consent (22%) and loss to follow-up (7%), with only 1.1% due to treatment-related adverse events. These findings are intended to support brilaroxazine's New Drug Application (NDA) submission to the FDA. The drug also holds potential for other neuropsychiatric and inflammatory indications, having received Orphan Drug Designation for PAH and IPF.

Key Decisions for Investors

• Investors should view these comprehensive Phase 3 OLE results as significantly de-risking brilaroxazine's clinical profile for schizophrenia, potentially positioning Reviva favorably ahead of its planned FDA registration submission.
• Monitor Reviva's progress towards NDA submission and subsequent FDA interactions, as successful regulatory milestones will be key catalysts for the stock; the strong efficacy, particularly in negative symptoms, and favorable safety profile address unmet needs in schizophrenia treatment.
• Consider the 35% discontinuation rate in the context of its primary non-adverse event drivers, but acknowledge that real-world patient adherence will be a critical factor for commercial success if approved.
• Evaluate the long-term potential upside from brilaroxazine's broader applicability in other CNS and inflammatory indications, which could offer diversified revenue streams beyond schizophrenia.